Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Clarksterh who wrote (23768)	5/23/2007 11:16:52 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Was it something in the Press Release vs the article itself? It's in the article itself (Table IV). I see your point about the exclusion when you explain this from a purely cook-book statistical perspective, but from an intuitive perspective, if we have large trials with no events in either arm, then surely that says something about the both the absolute and relative (to placebo) risk from the drug. From a purely statistical perspective, the methodology doesn't know, for example, that a "no event" trial wasn't conducted in a population of 15-year-olds with essentially no cardiac risk, in which case excluding the trial is entirely appropriate, or whether the population was relatively homogeneous with the other trials, in which case excluding the information from the no-event trial biases the analysis. Statistics is a lot harder than it looks! Peter